ExpiresJanuary 31, 2021
Penn State College of Medicine
Non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD), is a severe liver disorder with a rapidly progressive course that can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. In order to prevent irreversible liver damage, patients with NASH should receive immediate treatment. However, distinguishing NASH from other liver disorders and identifying high-risk patients remain challenges, and there are limited treatment options once a patient is diagnosed. While there are no approved medical therapies for NASH, multiple investigational agents have shown promise in late-stage trials and are expected to be available for NASH treatment soon.
Breakthroghs with NASH Management: What Do Gastroenterologists and Hepatologists Need to Know? will provide clinicians with the most current guidance on NASH diagnostic strategies. Clinician learners will also receive information on the efficacy, safety, and potential use of novel agents in late-stage clinical investigation for the treatment of patients with NASH.
ABMS Member Board Approvals by Type
ABMS MOC Part II CME Activity
NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
-Implement guideline- and expert-recommended strategies to diagnose NASH and evaluate its severity
-Evaluate the safety and efficacy data for the NASH therapies in late-stage development
NASH, NAFLD, Hepatology, Liver Disease
Interpersonal & Communication Skills, Medical Knowledge, Patient Care & Procedural Skills, Practice-based Learning & Improvement
CME Credit Type
AMA PRA Category 1 Credit
Academic Medicine, Outpatient, Rural, Urban, VA/Military